# Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

> **NCT04085458** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Damoctocog alfa pegol (Jivi, BAY94-9027)

## Key facts

- **NCT ID:** NCT04085458
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-08-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085458, "Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04085458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*